Updates on Management of Parkinson’s Disease Treatment
Parkinson’s disease is a central nervous system syndrome which affects the motor neuron, mainly characterized by rigidity, tremor, depression, dementia, and so on. Treatment for this disease is mostly symptomatic and almost no curative treatment alternatives are available. Risk of Parkinson’s illness is expected to grow with age and the infection mainly affects individuals who are above 50 years. The major endeavor of the Parkinson’s illness treatment is to offer control on symptoms and signs, for instance, difficulty with walking, shakiness in hands, slowness of movement, and so on.
Advances in management of motor symptoms of Parkinson’s disease (PD) have been seen in recent years in both medical management and surgical management. However, both PD patients and their physicians may not be familiar with the increasing options and therefore may not be taking advantage of available treatments.
Get PDF Brochure at: https://bit.ly/2RTBoKZ
Latest developments in Parkinson’s disease treatment, for instance, combination treatments to prolong the action of unremitting dopaminergic stimulation medicines, support for neurostimulation tools, neuroprotective treatment to slow down prediction of a disease, neural transplantation and gene therapy, and so on, are anticipated to bring huge development in global Parkinson’s disease treatment market in the coming future. In addition, growing aging inhabitants, the occurrence of Parkinsonism across the globe are the major aspects propelling the demand and requirement for the global Parkinson’s disease treatment market. Also, increasing old age inhabitants and higher occurrences of the neurodegenerative syndrome are two important aspects that are likely to fuel the development of the global Parkinson’s disease treatment market. In addition, growing R&D venture and a number of medicines in the pipeline are further projected to propel the market development. On the other hand, high expenditure of treatment and short of proficiency for early diagnosis is anticipated to curtail the market development.
Some of the most important market players in the Parkinson’s disease treatment market are Salix Pharmaceuticals, GlaxoSmithKline Plc., Teva Pharmaceutical Industries Ltd., Impax Laboratories, Inc., Orion Corporation, Novartis AG, Par Pharmaceutical, Mylan N.V., Daiichi Sankyo, Cipla Inc., Wockhardt Limited, and Apotex Inc., among others.
The global Parkinson’s disease treatment market is fragmented in terms of drug type and geography. On the basis of drug type, the market is classified into, pipeline and marketed drugs. The marketed drugs division are further categorized into Dopamine agonists, Levodopa, Glutamate antagonist, Apomorphine, COMT inhibitors Anticholinergics, and MAO-B inhibitors.
Source: The Insight Partners